Preclinical

Every post on preclinical, newest first.

Posts

StudiesOct 20, 20265 min read
Tirzepatide showed fewer heart failure events than dulaglutide
A new analysis from SURPASS-CVOT compared tirzepatide and dulaglutide in people with type 2 diabetes and heart failure. It found tirzepatide was linked to fewer heart failure events, though the result is exploratory.

Compound pages

The evergreen research summaries these posts build on.

DulaglutideOnce-weekly GLP-1 agonist for type 2 diabetes and heart-risk reduction.ExenatideA GLP-1 receptor agonist studied for diabetes and weight.LiraglutideA once-daily GLP-1 injection approved for weight loss and diabetes.